The Weight-Loss Pill Is Here — So Why Is Mounjaro Still Better?

It has finally happened: the weight-loss pill is real. Orforglipron — sold as Foundayo — became the first oral GLP-1 medicine approved for weight loss with no food or water restrictions, a once-a-day tablet instead of an injection. That is genuinely exciting, and it will appeal to a lot of people who never wanted a needle. But here is the honest headline I want to give you as a clinician: it is not as good as Mounjaro — and the reason why is a lovely piece of biology worth understanding.

Quick recap: why a pill was hard in the first place

The reason we have injections at all is chemistry. The original GLP-1 drugs — Ozempic and Wegovy (semaglutide), and the GLP-1 side of Mounjaro — are peptides: short chains of amino acids held together by peptide bonds. Swallow a peptide and your gut destroys it. The stomach and small bowel are full of proteases (peptidases) whose entire job is to cut peptide bonds, and in the blood an enzyme called DPP-4 — an exopeptidase — clips the ends off. That is why peptide GLP-1 drugs go in a syringe: taken by mouth, they are shredded before they can work.

Orforglipron gets around all of that by not being a peptide at all. It is a small molecule with no peptide bonds, so the proteases and DPP-4 have nothing to cut — it survives the gut and is absorbed intact, no absorption enhancer and no empty-stomach routine required. I built that story up from the chemistry in a separate piece: Orforglipron explained: the oral GLP-1 pill with no needle. Here I want to focus on the more interesting clinical question — now that the pill exists, how good is it?

The catch: one receptor versus two

Orforglipron does one job: it switches on the GLP-1 receptor. That single action gives you the whole GLP-1 package — glucose-dependent insulin release, less glucagon from the liver, slower gastric emptying, and appetite suppression in the brain. It is real, useful weight loss.

Mounjaro (tirzepatide) does two jobs. It is a dual agonist: it activates the GLP-1 receptor and a second one, the GIP receptor. GIP stands for glucose-dependent insulinotropic polypeptide — like GLP-1, it is an incretin, a gut hormone that ramps up insulin when blood glucose is high. Hitting both receptors at once appears to do more than hitting one, which is why, across the trial programmes so far, the dual-agonist injection has generally driven larger average weight loss than a GLP-1-only drug.

What the second receptor (GIP) actually adds

This is the part that sounds counter-intuitive, so stay with me. Adding GIP activity seems to boost both appetite control and, importantly, fat and lipid metabolism. Part of the story researchers point to is an effect on glucagon and on lipolysis — the breakdown of stored fat. In other words, the second receptor doesn't just repeat what GLP-1 is already doing; it seems to nudge how the body handles fat, adding to the overall result.

I'll be straight with you: the exact mechanism of GIP in weight loss is still debated — there's genuine scientific argument about how much comes from the brain, the pancreas, or fat tissue directly. But the clinical bottom line is not really in dispute: GLP-1 plus GIP does more than GLP-1 alone. That's the whole reason the dual agonist was built.

Orforglipron vs Mounjaro at a glance

A fair-warning note on that table: these are broad patterns from separate trial programmes, not a like-for-like head-to-head at matched doses. Treat "generally greater" as the honest direction of travel, not a precise promise for any one patient.

So why does the pill still matter?

Because not everyone wants an injection. For a lot of people the needle is the reason they never start — and a treatment only works if the patient will actually take it. A once-daily tablet with no fasting window strips out two big barriers at once, and I think it opens weight-loss treatment up to a whole group of people who were never going to inject. Expect another boom in demand off the back of it.

The way I'd frame it clinically: the injection is still the most powerful single tool, but the pill is the one that reaches the people the injection never would. Both have a place.

The bit no drug replaces

Whichever one a patient is on, the honest advice doesn't change: the medicine is a tool, not a cure. It works best coupled with what actually keeps weight off — controlling what you eat, regular exercise, and, within reason, resistance training. That last one matters more than people realise: it protects muscle while you lose fat, and the goal was never just a smaller number on the scale, it's being genuinely healthier. Always give people the holistic picture, not just a prescription.

Want to prescribe in this space?

Weight-loss prescribing is about to get busy again, and the clinicians who do it well are the ones who actually understand the pharmacology underneath — not just the brand names. If you want to develop your skills in prescribing for weight loss, or make sense of where these medicines are heading, that's exactly the kind of teaching I do. Get in touch and I'm happy to help.

And if you're looking to build your skills in ADHD, keep an eye out for my ADHD webinar — it's the same idea: take something that looks intimidating and rebuild it from first principles so it sticks.

Work with me

Frequently asked questions